These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36725119)

  • 1. Treatment approaches for patients with TP53-mutated mantle cell lymphoma.
    Lew TE; Minson A; Dickinson M; Handunnetti SM; Blombery P; Khot A; Anderson MA; Ritchie D; Tam CS; Seymour JF
    Lancet Haematol; 2023 Feb; 10(2):e142-e154. PubMed ID: 36725119
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Eskelund CW; Dahl C; Hansen JW; Westman M; Kolstad A; Pedersen LB; Montano-Almendras CP; Husby S; Freiburghaus C; Ek S; Pedersen A; Niemann C; Räty R; Brown P; Geisler CH; Andersen MK; Guldberg P; Jerkeman M; Grønbæk K
    Blood; 2017 Oct; 130(17):1903-1910. PubMed ID: 28819011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in
    Lew TE; Cliff ERS; Dickinson M; Tam CS; Seymour JF; Blombery P; Bajel A; Ritchie D; Khot A
    Leuk Lymphoma; 2023; 64(11):1792-1800. PubMed ID: 37531077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Directions for Mantle Cell Lymphoma in 2022.
    Kumar A; Eyre TA; Lewis KL; Thompson MC; Cheah CY
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-15. PubMed ID: 35561299
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Ferrero S; Rossi D; Rinaldi A; Bruscaggin A; Spina V; Eskelund CW; Evangelista A; Moia R; Kwee I; Dahl C; Di Rocco A; Stefoni V; Diop F; Favini C; Ghione P; Mahmoud AM; Schipani M; Kolstad A; Barbero D; Novero D; Paulli M; Zamò A; Jerkeman M; da Silva MG; Santoro A; Molinari A; Ferreri A; Grønbæk K; Piccin A; Cortelazzo S; Bertoni F; Ladetto M; Gaidano G
    Haematologica; 2020 Jun; 105(6):1604-1612. PubMed ID: 31537689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TP53 Mutation and Complex Karyotype Portends a Dismal Prognosis in Patients With Mantle Cell Lymphoma.
    Obr A; Procházka V; Jirkuvová A; Urbánková H; Kriegova E; Schneiderová P; Vatolíková M; Papajík T
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):762-768. PubMed ID: 30146365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling and management of mantle cell lymphoma.
    Ruan J
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):30-40. PubMed ID: 31808882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage.
    Dong HJ; Zhou LT; Fang C; Fan L; Zhu DX; Wang YH; Li JY; Xu W
    Med Oncol; 2012 Sep; 29(3):2166-73. PubMed ID: 22057359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Risk Mantle Cell Lymphoma in the Era of Novel Agents.
    Nabrinsky E; Danilov AV; Koller PB
    Curr Hematol Malig Rep; 2021 Feb; 16(1):8-18. PubMed ID: 33507515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.
    Jing C; Zheng Y; Feng Y; Cao X; Xu C
    Sci Rep; 2021 Jun; 11(1):11896. PubMed ID: 34099776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
    Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
    Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
    Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
    Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma.
    Obr A; Klener P; Furst T; Kriegova E; Zemanova Z; Urbankova H; Jirkuvova A; Petrackova A; Malarikova D; Forsterova K; Cudova B; Sedlarikova L; Berkova A; Kasalova N; Papajik T; Trneny M
    Br J Haematol; 2020 Dec; 191(5):e103-e106. PubMed ID: 32862455
    [No Abstract]   [Full Text] [Related]  

  • 14. p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
    Rodrigues JM; Hassan M; Freiburghaus C; Eskelund CW; Geisler C; Räty R; Kolstad A; Sundström C; Glimelius I; Grønbaek K; Kwiecinska A; Porwit A; Jerkeman M; Ek S
    Br J Haematol; 2020 Dec; 191(5):796-805. PubMed ID: 32748433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.
    Slotta-Huspenina J; Koch I; de Leval L; Keller G; Klier M; Bink K; Kremer M; Raffeld M; Fend F; Quintanilla-Martinez L
    Haematologica; 2012 Sep; 97(9):1422-30. PubMed ID: 22315488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which Patients With Mantle Cell Lymphoma Do Not Need Aggressive Therapy.
    Ruan J; Martin P
    Curr Hematol Malig Rep; 2016 Jun; 11(3):234-40. PubMed ID: 27068437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
    Vose JM
    Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
    Tam CS; Anderson MA; Pott C; Agarwal R; Handunnetti S; Hicks RJ; Burbury K; Turner G; Di Iulio J; Bressel M; Westerman D; Lade S; Dreyling M; Dawson SJ; Dawson MA; Seymour JF; Roberts AW
    N Engl J Med; 2018 Mar; 378(13):1211-1223. PubMed ID: 29590547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of
    Eskelund CW; Albertsson-Lindblad A; Kolstad A; Laurell A; Räty R; Pedersen LB; Geisler CH; Jerkeman M; Grønbæk K
    Haematologica; 2018 Nov; 103(11):e541-e543. PubMed ID: 29794145
    [No Abstract]   [Full Text] [Related]  

  • 20. Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.
    Salek D; Vesela P; Boudova L; Janikova A; Klener P; Vokurka S; Jankovska M; Pytlik R; Belada D; Pirnos J; Moulis M; Kodet R; Michal M; Janousova E; Muzik J; Mayer J; Trněný M
    Leuk Lymphoma; 2014 Apr; 55(4):802-10. PubMed ID: 23772666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.